Royalty Management (Nasdaq: RMCO), an innovative royalty company building shareholder value by acquiring and developing high value assets in sustainable market environments, announced that it has established a division of the Company that focuses on investment and development of the domestic energy storage and energy efficiency markets, with an initial focus on investing in the raw material supply chain of critical minerals by financing the creation of feedstock inventories from sources around the globe, to be later used in the refining of these strategic materials into high-grade materials for the creation of products focused on energy storage and efficiency, such as batteries and high-efficiency, permanent magnets.

1847 Holdings (NYSE American: EFSH), a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, today announced that it will effect a 1-for-4 reverse split ("reverse split") of its common shares that will become effective on January 8, 2024. "We continue to execute on our strategy of acquiring undervalued, cash flow positive, lower-middle market businesses at attractive valuations," stated Ellery W. Roberts, CEO of 1847. "Nevertheless, the overall capital markets remain challenging, and we believe this reverse split will tighten the public float in our stock, enabling us to attract a broader universe of institutional and other investors given the traction in our business. This strategic restructuring as part of the Company's capitalization acknowledges that reality and better positions the Company for our serial accretive acquisitions going forward.”

BullFrog AI (Nasdaq: BFRG), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to shareholders from its CEO Vin Singh.

Aditxt (Nasdaq: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrant in lieu thereof) and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is being offered in the offering together with warrants to purchase two shares of common stock at an exercise price of $4.60 per share.